Could high levels of tissue polypeptide specific antigen, a marker of apoptosis detected in nonalcoholic steatohepatitis, improve after weight loss?
BACKGROUND
Tissue Polypeptide Specific antigen has recently been proposed as diagnostic marker of apoptosis in NonAlcoholic SteatoHepatitis. The aim of this study was to validate in patients suffering from NonAlcoholic SteatoHepatitis the clinical utility of this marker after different programs of weight reduction.


METHODS
Overweight/obese patients with visceral adiposity and liver histology compatible were assigned to a Calorically-Restricted diet (n = 22), a Calorically-Restricted diet plus EXercise (n = 19) or No Healthy Life Style (control group, n = 21) for six months. The presence of Body-Weight loss was assessed by a Body Mass Index decrease of at least three points. Serum ALanine aminoTransferase, HOmeostasis Model Assessment method value and Tissue Polypeptide Specific antigen concentrations were determined at time 0, after 3 and 6 months in both the Intervention groups and in the controls' one.


RESULTS
In NonAlcoholic SteatoHepatitis patients who obtained Body-Weight reduction, a significant decrease of the serum Tissue Polypeptide Specific antigen values was showed with a clear linear trend across time, P = 0.0001. Decrement of Tissue Polypeptide Specific antigen concentrations best differentiated the Body-Weight loss from the body-weight maintenance in respect to Tissue Polypeptide Specific antigen and HOmeostasis Model Assessment method values.


CONCLUSIONS
This study support the clinical utility of serum Tissue Polypeptide Specific antigen antigen levels in the follow-up of overweight/obese patients with NonAlcoholic SteatoHepatitis on weight reduction programs.
Tarantino
Giovanni
G
Department of Clinical and Experimental Medicine, Federico II University, Medical School of Naples, Italy. tarantin@unina.it
Mazzarella
Claudia
C
Tarantino
Marianna
M
Di Minno
Matteo Nicola Dario
MN
Conca
Paolo
P
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000886:Anthropometry; D017209:Apoptosis; D015415:Biomarkers / Q000097:blood*; D015992:Body Mass Index; D031204:Caloric Restriction; D003430:Cross-Sectional Studies; D005234:Fatty Liver / Q000097:blood* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000473:pathology; D050177:Overweight / Q000097:blood / Q000473:pathology; D010455:Peptides / Q000097:blood*; D010865:Pilot Projects; D015431:Weight Loss
D015415:Biomarkers; D010455:Peptides; C089984:tissue polypeptide specific antigen; D000410:Alanine Transaminase